关于我们
GeoVax Labs, Inc., (NASDAQ: GOVX) is a clinical-stage biotechnology company developing human vaccines against infectious diseases using our Modified Vaccinia Ankara - Virus-Like Particle (MVA-VLP) vaccine platform. Our current development programs are focused on vaccines against COVID-19; Hemorrhagic Fever viruses such as Ebola (Zaire, Sudan), Lassa and Marburg; Malaria and Zika virus; and, Human Immunodeficiency Virus (HIV). We have also initiated programs to develop a broadly applicable immunotherapy against tumor associated antigen MUC1 that is expressed of many solid tumor types including breast, ovarian, gastric, liver, pancreas, renal and lymph nodes and immunotherapy to treat human papilloma virus (HPV)-induced cancers. For more information, visit www.geovax.com.
- 网站
-
https://www.geovax.com
GeoVax Labs, Inc.的外部链接
- 所属行业
- 生物技术研究
- 规模
- 11-50 人
- 总部
- Smyrna，GA
- 类型
- 上市公司
- 领域
- HIV/AIDS vaccine development、Zika virus vaccine、Malaria vaccine、Hemorrhagic fever virus vaccine、Hepatitis B vaccine、Ebola vaccine、Cancer vaccine development、Lassa Fever vaccine、Immuno-oncology、biotechnology和COVID-19
地点
-
主要
获取路线
1900 Lake Park Drive
Suite 380
US，GA，Smyrna，30080
GeoVax Labs, Inc.员工
动态
-
GeoVax Response to WHO’s Third Declaration of #Mpox as a Public Health Emergency of International Concern. $GOVX https://buff.ly/4klWihM
-
-
Mpox Clade 1 in the U.S. Highlights the Need for Vaccine Supply Diversification https://buff.ly/3QndUvV
-
GeoVax Pledges Continued Support for Vaccine Innovation, Transparency, and Public Health https://buff.ly/4k7fTlp
-
GeoVax Congratulates Dr. Valerie Montgomery Rice, President and CEO of Morehouse School of Medicine (as well as Special Advisor to the Chairman, CEO, and Board of Directors of GeoVax) on Receiving the 2025 Healthcare Champions Lifetime Achievement Award https://buff.ly/4hx8XfU
-